Curis (NASDAQ:CRIS) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Thursday, ValuEngine reports.

Shares of Curis stock traded down $0.05 during trading hours on Thursday, reaching $1.39. 156,400 shares of the company’s stock were exchanged, compared to its average volume of 311,121. Curis has a 52-week low of $0.60 and a 52-week high of $2.90. The company has a fifty day moving average of $2.00 and a 200-day moving average of $1.93.

Several institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC lifted its stake in shares of Curis by 20.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,191,419 shares of the biotechnology company’s stock worth $2,216,000 after purchasing an additional 203,590 shares during the period. Fosun International Ltd lifted its stake in shares of Curis by 46.6% during the 2nd quarter. Fosun International Ltd now owns 581,834 shares of the biotechnology company’s stock worth $1,065,000 after purchasing an additional 184,965 shares during the period. BlackRock Inc. lifted its stake in shares of Curis by 15.2% during the 2nd quarter. BlackRock Inc. now owns 487,816 shares of the biotechnology company’s stock worth $908,000 after purchasing an additional 64,262 shares during the period. BB&T Securities LLC lifted its stake in shares of Curis by 131.6% during the 3rd quarter. BB&T Securities LLC now owns 43,994 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 25,000 shares during the period. Finally, Cetera Advisor Networks LLC purchased a new position in shares of Curis during the 2nd quarter worth $42,000. 22.04% of the stock is currently owned by institutional investors.

Curis Company Profile

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.

Featured Story: What is meant by holder of record?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.